Premium
O2‐02‐03: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden
Author(s) -
Rentz Dorene M.,
Mormino Elizabeth C.,
Amariglio Rebecca,
Papp Kathryn V.,
Sperling Reisa A.,
Johnson Keith A.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.138
Subject(s) - pittsburgh compound b , dementia , positron emission tomography , neuropsychology , cognitive decline , psychology , medicine , temporal lobe , amyloid (mycology) , cognitive reserve , cognition , nuclear medicine , neuroscience , pathology , disease , epilepsy
and non-carriers. We also sought to determine the extent to which ε4 carriage moderated EM decline in prodromal AD over the same interval. Methods:CN older adults (n1⁄4333) and adults with MCI (n1⁄456) enrolled in the Australian Imaging, Biomarkers and Lifestyle study underwent Ab neuroimaging and ε4 genotyping. EM was assessed at baseline, 18-, 36-, 54and 72-month followups. Ab PET neuroimaging was used to classify participants as Abor Ab+. Results:Relative to Ab-ε4CNs, both Ab+ε4+ CNs and Ab+ε4CNs showed significantly faster rates decline on EM over 72-months; however, Ab+ε4+ CNs showed significantly faster decline than Ab+ε4CNs (Figure 1). Relative to Ab-ε4CNs, both Ab+ε4MCIs and Ab+ε4+ MCIs showed significantly faster rates of EM decline of a large magnitude over 72-months. There were no differences in rates of EM change between Ab-ε4CNs and Ab-ε4+ CNs. Similarly, there were no differences in rates of EM change between Ab-ε4CNs and Ab-ε4MCIs (Figure 1). Conclusions:The results show for the first time that in CN older adults, Ab+ is associated with EM decline in ε4 non-carriers; however, the rate of this decline is much slower than that for ε4 carriers. Once individuals’ EM impairment is sufficient to meet clinical criteria for MCI, Ab related EM decline is unaffected by ε4 carriage. Thus, Ab and ε4 carriage act synergistically act to moderate the development of AD.